肠道活菌制剂对慢性阻塞性肺疾病急性加重患者的疗效  

Therapeutic Effect of Intestinal Living Bacterium Preparation on the Patients of AECOPD

作　　者：杨超 杜俊毅[1] 蒲丹 许小靓 陈敏[1] 刘翱 YANG Chao;DU Jun-yi;PU Dan;XU Xiao-liang;CHEN Min;LIU AO(Dept.of Respiratory and Critical Care Medicine,The First People's Hospital-Calmette Hospital of Kunming;Dept.of Laboratory,The First People's Hospital-Calmette Hospital of Kunming,Kunming Yunnan 650224,China)

机构地区：[1]昆明市第一人民医院甘美医院呼吸与危重症医学科,云南昆明650224 [2]昆明市第一人民医院甘美医院检验科,云南昆明650224

出　　处：《昆明医科大学学报》2020年第9期120-124,共5页Journal of Kunming Medical University

基　　金：昆明市西山区科技计划基金资助项目(西科字22号)。

摘　　要：目的探讨肠道活菌制剂对慢性阻塞性肺疾病急性加重(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者的治疗效果。方法选择2019年5月至10月昆明市第一人民医院甘美医院呼吸与危重症医学科60名AECOPD住院患者为研究对象,随机分为对照组(常规治疗)和治疗组(常规治疗+肠道活菌制剂)各30例。治疗2周后,比较两组在呼吸困难评分、肺功能、大便菌群球杆比失衡发生率、大便中双歧杆菌及乳酸杆菌、住院天数之间的差异。分析肠道活菌制剂的安全性。结果治疗组治疗后大便菌群中球杆比失衡发生率较对照组治疗后明显下降,差异有统计学意义(P<0.05);治疗组、对照组治疗后MMRC均较治疗前下降,差异均有统计学意义(P<0.05);治疗组、对照组治疗后FEV1%pre均较治疗前升高,差异均有统计学意义(P<0.05);治疗组治疗后大便双歧杆菌及乳酸杆菌Ct值较治疗前均下降,差异均有统计学意义(P<0.05);对照组治疗后大便双歧杆菌及乳酸杆菌Ct值较治疗前均升高,差异均有统计学意义(P<0.05);治疗组与对照组治疗后大便双歧杆菌及乳酸杆菌Ct值差异均有统计学意义(P<0.05);治疗组治疗前后的MMRC、大便双歧杆菌及乳酸杆菌Ct值的差值与对照组治疗前后差值之间均有统计学意义(P<0.05);治疗组的住院天数短于对照组,差异有统计学意义(P<0.05)。肠道活菌制剂治疗过程中无不良安全事件出现。结论肠道活菌制剂治疗AECOPD,可以降低患者大便菌群中球杆比失衡发生率、降低MMRC评分,改善肺功能,改善患者肠道益生菌群,缩短住院时间,安全性好。Objective To investigate the therapeutic effect of intestinal living bacterium preparation on the patients of acute exacerbation of chronic obstructive pulmonary disease.Methods From May to October 2019,sixty inpatients of AECOPD in the Dept.of Respiratoty and Critical Care Medicine of the 1st People's Hospital of Kunming were enrolled as the research objects.They were randomly divided into the control group(with conventional therapy,n=30)and the treatment group(with conventional therapy+intestinal living bacterium preparation,n=30).After the two weeks of treatment,the dyspnea scores,lung function,incidence of coccil-to-bacillus imbalance in stool flora,and bifidobacterium and lactobacillus in stool flora and the length of stay in the hospital were compared between the two groups before and after the treatment.And the therapeutic safety of intestinal living bac terium preparation was analyzed.Results The incidence of coccil-to-bacillusimbalance instool flora in the treatment group after the treatment was significantly lower than that in the control group(P<0.05);the MMRC of the treatment group and control group after the treatment all decreased than that before the treatment,and the difference was all statistically significant(P<0.05);the FEV1%pre of the treatment group and control group after the treatmentall increased than that before the treatment,and the difference was all statistically significant(P<0.05);the Ct value of bifidobacterium and lactobacillus in the treatment group was lower than that before the treatment,the difference was statistically significant(P<0.05);the Ct value of bifidobacterium and lactobacillus in the control group after the treatment was higher than that before the treatment,and the difference was statistically significant(P<0.05);the difference of MMRC,the Ct value of bifidobacterium and lactobacillus before and after the treatment in the treatment group was all statistically significant compared with that before and after the treatment in the control group(P<0.05);the length of sta

关 键 词：肠道活菌制剂 慢性阻塞性肺疾病急性加重 治疗 效果 

分 类 号：R563[医药卫生—呼吸系统]